AstraZeneca shares slide 7% after reports of Bristol Myers talks - Reuters

AstraZeneca shares slide 7% after reports of Bristol Myers talks  Reuters

AstraZeneca Is Said to Have Explored Bristol Myers Merger

AstraZeneca has explored an acquisition of Bristol Myers Squibb, according to people familiar with the matter. It’s unclear if discussions are ongoing or whether they will result in a transaction, the people cautioned. A representative for AstraZeneca declined to comment and Bristol Myers Squibb couldn’t immediately be reached for comment on the talks. Bloomberg's Manuel Baigorri reports. (Source: Bloomberg)

AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks - WSJ

AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks  WSJ

FirstFT: AstraZeneca and Bristol Myers Squibb discuss $400bn tie-up

Also in today’s newsletter: Ceuta migrant crossing and Uefa’s response to failed Fifa plan

AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger

Tie-up would be one of the biggest pharmaceutical deals ever and create the world’s fourth-largest drugmaker Business live – latest updates Britain’s biggest drugmaker AstraZeneca is in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group. AstraZeneca, run by longtime chief executive Pascal Soriot, is the second-biggest listed company in the UK, with a market value of nearly £196bn. BMS, headquartered in Princeto...

By Julia Kollewe

AstraZeneca shares fall on Bristol Myers Squibb merger talks - The Times

AstraZeneca shares fall on Bristol Myers Squibb merger talks  The Times

AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb

The companies have discussed a potential merger over several months, the Financial Times reported on Sunday.

AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.

AstraZeneca shares were slumping while Bristol-Myers Squibb was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.

By Steve Goldstein

AstraZeneca in talks over £300bn mega-merger with US rival – reports

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

By Henry Saker-Clark

AstraZeneca plots £300bn tie-up with US rival

AstraZeneca in talks over potential Bristol-Myers Squibb megadeal that would create world’s biggest drugmaker

By Kelly Gilblom